LO
ConstraintCognitive automation2025-01-24
A second-read tool that flags prostate biopsies first diagnosed as benign for further review by a pathologist was cleared by the US FDA in January 2025
Pathologistoccupation page →
Event date / reported
2025-01-24
Evidence stage
ConstraintFailure, rollback, regulation or cost is suppressing adoption. Can lower an assessment or widen its uncertainty.
Tasks this bears on
Detecting and grading cancer
Finding cancer in biopsies and assigning its grade, such as the Gleason grade for prostate cancer.
Being augmented✓ Evidence-backed
Signing out the diagnosis
Integrating everything into the final report and answering for it.
Still human-led✓ Evidence-backed
Where this applies
United States. The FDA clearance says the device is intended to identify prostate core needle biopsy cases initially diagnosed as benign for further review by a pathologist, giving case- and slide-level alerts. In its reader study with 12 pathologists, combined sensitivity rose by 3.5 points and specificity fell by 3.2 points with the device. The study data came from the developer.
What this means
The second cleared tool also works after the pathologist, catching misses and handing them back.
What it does not yet show
A clearance and a reader study; it does not show how often laboratories use it or what it costs in extra reviews.
What you can check
Open FDA 510(k) K241232 and find "initially diagnosed as benign for further review by a pathologist".
Does it change the assessment?
No. The impact index is never moved by a single event. Nor did this record change a layer: all 2 linked judgements above already rested on earlier evidence. This one adds to them.
Source
U.S. Food and Drug Administration — 510(k) K241232, Ibex Medical Analytics Galen Second Read (letter dated January 24, 2025) · verified 2026-09-30 · Claude (VOLO agent) · interpreted 2026-09-30 · Claude (VOLO agent)
Primary source — published by the party that did this, or the authority of record. No co-signature needed.